Innovation Pharmaceuticals Inc (IPIX)

[frrol]

The filing repeats the definition, so as long as there is any statistically reliable difference between arms at a 95% confidence interval, Aspire has to buy. If it's 32% vs 31%, a judge would make them buy.

$2,000,000 of additional securities, provided that on or before September 30, 2018, the Company announces that its Phase 2b trial of Prurisol on psoriasis has met its primary end point, which means a statistically significant increase (p<0.05) in the proportion of patients achieving at least a 75% reduction from baseline in PASI score (PASI75) while receiving Prurisol compared to those receiving placebo at the end of 12 weeks